Andrew L Coveler - JoVE Visualize

Showing results (41-50 of 52) with videos related to

Pageof 6

Sort By:

Oncotarget|August 11, 2016

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumorsC Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.

Contemporary Clinical Trials|June 28, 2023

Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility studyStacey A Cohen, Susan Veleber, Jonathan Siman, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2023

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced MalignanciesBenedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.

Nature Medicine|April 14, 2026

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trialDevalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.

Nature Communications|January 12, 2026

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysisJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.

Journal for Immunotherapy of Cancer|June 29, 2023

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.

Cancers|June 13, 2025

Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary CancersGentry G King, Kelsey K Baker, Andrew L Coveler, et al.

JAMA Network Open|January 9, 2024

Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical TrialHannah M Thompson, Dana M Omer, Sabrina Lin, et al.

The New England Journal of Medicine|September 21, 2020

KRASG12C Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.

Journal for Immunotherapy of Cancer|January 25, 2024

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.

Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:

Pageof 6

Oncotarget|August 11, 2016

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumorsC Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.

Contemporary Clinical Trials|June 28, 2023

Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility studyStacey A Cohen, Susan Veleber, Jonathan Siman, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2023

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced MalignanciesBenedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.

Nature Medicine|April 14, 2026

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trialDevalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.

Nature Communications|January 12, 2026

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysisJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.

Journal for Immunotherapy of Cancer|June 29, 2023

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.

Cancers|June 13, 2025

Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary CancersGentry G King, Kelsey K Baker, Andrew L Coveler, et al.

JAMA Network Open|January 9, 2024

Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical TrialHannah M Thompson, Dana M Omer, Sabrina Lin, et al.

The New England Journal of Medicine|September 21, 2020

KRASG12C Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.

Journal for Immunotherapy of Cancer|January 25, 2024

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.

Pageof 6